More than 30,000 medical professionals and scientists sign Great Barrington Declaration demanding an end to lockdowns

More than 30,000 medical professionals and scientists sign Great Barrington Declaration demanding an end to lockdowns

As of October 13th, 9,227 medical and health scientists as well as 23,943 medical practioners have signed the Great Barrington Declaration. The declaration has been censored across social media as Governments and their tech allies have sought to conceal the fact that there is no global concensus that lockdowns work, or that they should be used at all. As the declaration began to gain steam the World Health Organisation appears to have walked back their stance on lock downs.

The Great Barrington Declaration – As infectious disease epidemiologists and public health scientists we have grave concerns about the damaging physical and mental health impacts of the prevailing COVID-19 policies, and recommend an approach we call Focused Protection.

Coming from both the left and right, and around the world, we have devoted our careers to protecting people. Current lockdown policies are producing devastating effects on short and long-term public health. The results (to name a few) include lower childhood vaccination rates, worsening cardiovascular disease outcomes, fewer cancer screenings and deteriorating mental health – leading to greater excess mortality in years to come, with the working class and younger members of society carrying the heaviest burden. Keeping students out of school is a grave injustice.

Keeping these measures in place until a vaccine is available will cause irreparable damage, with the underprivileged disproportionately harmed.

Fortunately, our understanding of the virus is growing. We know that vulnerability to death from COVID-19 is more than a thousand-fold higher in the old and infirm than the young. Indeed, for children, COVID-19 is less dangerous than many other harms, including influenza.

As immunity builds in the population, the risk of infection to all – including the vulnerable – falls. We know that all populations will eventually reach herd immunity – i.e. the point at which the rate of new infections is stable – and that this can be assisted by (but is not dependent upon) a vaccine. Our goal should therefore be to minimize mortality and social harm until we reach herd immunity.

The most compassionate approach that balances the risks and benefits of reaching herd immunity, is to allow those who are at minimal risk of death to live their lives normally to build up immunity to the virus through natural infection, while better protecting those who are at highest risk. We call this Focused Protection.

Adopting measures to protect the vulnerable should be the central aim of public health responses to COVID-19. By way of example, nursing homes should use staff with acquired immunity and perform frequent PCR testing of other staff and all visitors. Staff rotation should be minimized. Retired people living at home should have groceries and other essentials delivered to their home. When possible, they should meet family members outside rather than inside. A comprehensive and detailed list of measures, including approaches to multi-generational households, can be implemented, and is well within the scope and capability of public health professionals.

Those who are not vulnerable should immediately be allowed to resume life as normal. Simple hygiene measures, such as hand washing and staying home when sick should be practiced by everyone to reduce the herd immunity threshold. Schools and universities should be open for in-person teaching. Extracurricular activities, such as sports, should be resumed. Young low-risk adults should work normally, rather than from home. Restaurants and other businesses should open. Arts, music, sport and other cultural activities should resume. People who are more at risk may participate if they wish, while society as a whole enjoys the protection conferred upon the vulnerable by those who have built up herd immunity.

Read and sign the Declaration.

Johnson & Johnson Latest To Halt COVID-19 Vaccine Trial Over Unspecified Illness

Johnson & Johnson Latest To Halt COVID-19 Vaccine Trial Over Unspecified Illness

The study of Johnson & Johnson’s Covid-19 vaccine has been paused due to an unexplained illness in a study participant.

A document sent to outside researchers running the 60,000-patient clinical trial states that a “pausing rule” has been met, that the online system used to enroll patients in the study has been closed, and that the data and safety monitoring board — an independent committee that watches over the safety of patients in the clinical trial — would be convened. The document was obtained by STAT.

Contacted by STAT, J&J confirmed the study pause, saying it was due to “an unexplained illness in a study participant.” The company declined to provide further details.

“We must respect this participant’s privacy. We’re also learning more about this participant’s illness, and it’s important to have all the facts before we share additional information,” the company said in a statement.

J&J emphasised that so-called adverse events — illnesses, accidents, and other bad medical outcomes — are an expected part of a clinical study, and also emphasised the difference between a study pause and a clinical hold, which is a formal regulatory action that can last much longer. The vaccine study is not currently under a clinical hold. J&J said that while it normally communicates clinical holds to the public, it does not usually inform the public of study pauses.

The data and safety monitoring board, or DSMB, convened late Monday to review the case. J&J said that in cases like this “it is not always immediately apparent” whether the participant who experienced an adverse event received a study treatment or a placebo.

Though clinical trial pauses are not uncommon — and in some cases last only a few days — they are generating outsized attention in the race to test vaccines against SARS-CoV-2, the virus that causes Covid-19.

Continued at Statnews.com

How Gov Could Use RFID Chips When Millions of Americans Inject COVID-19 Vaccine

How Gov Could Use RFID Chips When Millions of Americans Inject COVID-19 Vaccine

Watch now: Interview with Jay Walker, CEO of Apiject Systems, whose company is in a $138 million public-private partnership with the White House called Project Jumpstart. Their job is to innovate a way to deliver millions of vaccines to Americans fast using eyedrop technology, and potentially using RFID Chips on a voluntary basis to track vaccine use to aid public health officials during potential future outbreaks.

ARVE Error: Mode: lazyload not available (ARVE Pro not active?), switching to normal mode




State Bar Group Calls for ‘Mandatory’ COVID-19 Vaccinations, Regardless of Objections

State Bar Group Calls for ‘Mandatory’ COVID-19 Vaccinations, Regardless of Objections

New York Law Journal

“Some Americans may push back on the COVID-19 vaccination for religious, philosophical or personal reasons,” says the report released on Thursday by the NYSBA, but, it says, “for the sake of public health, mandatory vaccinations for COVID-19 should be required in the United States as soon as it is available.”

Citing a robust collection of federal and state case law, a New York State Bar Association task-force group on Thursday said it should be mandatory for all Americans to have a COVID-19 vaccination, when one is available, including those who won’t want it for “religious, philosophical or personal reasons.”

Vitamin D, Quercetin, and Estradiol manifest properties of candidate medicinal agents for mitigation of the severity of pandemic COVID-19 defined by genomics-guided tracing of SARS-CoV-2 targets in human cells.

“Present analyses and numerous observational studies indicate that age-associated Vitamin D deficiency may contribute to the high mortality of older adults and the elderly. Immediate availability for targeted experimental and clinical interrogations of potential COVID-19 pandemic mitigation agents, namely Vitamin D and Quercetin, as well as of the highly selective (Ki, 600 pm) intrinsically-specific FURIN inhibitor (a1-antitrypsin Portland (a1-PDX), is considered an encouraging factor. Observations reported in this contribution are intended to facilitate follow-up targeted experimental studies and, if warranted, randomized clinical trials to identify and validate therapeutically-viable interventions to combat the COVID-19 pandemic. Specifically, gene expression profiles of Vitamin D and Quercetin activities and their established safety records as over-the-counter medicinal substances strongly argue that they may represent viable candidates for further considerations of their potential utility as COVID-19 pandemic mitigation agents. Significantly, the interventional randomized clinical trial entitled “Effect of Vitamin D Administration on Prevention and Treatment of Mild Forms of Suspected COVID-19” was listed on ClinicalTrials.gov website (https://www.clinicaltrials.gov/ct2/show/NCT04334005 ) with the starting date April 10 and completion date June 30, 2020.”

CHEMRXIV

Pin It on Pinterest